BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod
BeiGene blazed the trail for a growing wave of Chinese oncology drugs breaking through in the US with an initial approval for BTK inhibitor Brukinsa back in 2019, and now the US/Chinese drugmaker has set the stage for its lead drug’s next big act.
Brukinsa beat out a combination of chemotherapy bendamustine and Roche’s Rituxan in terms of extending the lives or halting the progression of disease in first-line patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), according to topline results from the Phase III SEQUOIA study unveiled Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.